What Women Investors find Attractive

Posted on June 9, 2021 by Admin

Women’s Investing Involvement is Growing Dramatically

Many consumer trends are driven by women. Fashion, diet, exercise, and even car design are heavily influenced by the gender that spends more time making purchasing decisions; statistically, this is women. As it relates to investing, past data suggest they have not been the trendsetters. When consumer monitoring company Cardingly examined user trends and attitudes toward cryptocurrency and Reddit-driven market moves, men were more likely to be on the “bandwagon” than women.

The Investment Gap is Closing (The Stats)

Using data from the same Cardingly report, the number of women involving themselves is, however, increasing. As a group, women are joining platforms in increasing numbers, transacting in the public markets, and driving a high percentage of the uptick in new account deposits.

“Our data shows women are increasingly taking control of their financial futures and considering new strategies,” said Esther Park, General Manager of Cardify.ai. “Still, our data reflects an ongoing need for both engagement with the marketplace and equality in the workplace as society takes strides toward equality.” Cardingly.ai

So far in 2021, compared to 2020, women using large popular platforms (TD Ameritrade, Fidelity, Robinhood, and Vanguard) have grown by 318%. The percentage increase from males grew at a slower 234%.

When compared to 2020, deposits in 2021 across popular platforms from women investors have grown by 318%. For the same period, deposits from male investors also spiked, but by a more modest 234%. The graph below demonstrates the percentage increase, on a monthly basis, of growth in account size. While males still have a higher overall deposit base, deposits from female investors accelerated from a 19.3% average in 2020 to 24.5% so far in 2021 (second chart below).

Source: Cardify.ai

Source: Cardingly

In addition to the growth in deposits, user numbers are also rising driven by the increase in women customers. Robinhood, for example, has seen substantial increases among women. User numbers on the app show a 209% increase among women from 2019 to 2020, this is double the 90.6% increase of men. Out of the four popular investment platforms analyzed by Cardingly, only TD Ameritrade experienced a greater increased proportion of men versus women users.

Source: Cardingly

The growth in the women user base continues in 2021. Robinhood has experienced the greatest relative gain

A survey of retail investors suggests information awareness is at different levels between men and women. One example shown is that over 30% of women responded they were not aware of the AMC and Gamestop trading frenzy in early 2021. This compares to 17% of men who responded they had no idea of the news story.

Cryptocurrency Trends

Women are not as experienced with crypto trading as men — 26% of women compared to 16% of men surveyed said they made their first cryptocurrency investment during the last six months. Similar to their investment accounts, deposits in cryptocurrency from women investors have jumped. Men’s deposits in crypto trading accounts have not grown at nearly the pace.

Source: Cardingly

To better understand the magnitude of growth, in January 2020 women had total deposits in crypto accounts representing 5.6% of total deposits. By the following January, women represented 15% of all deposits.

Source: Cardingly

Cryptocurrency allocations are now a bigger portion of women’s total portfolio. In 12 months, crypto went from 2% to 11%.

Results of the survey show women felt they were less informed related to crypto. A full 23% said their faith in crypto could increase with more information compared to 9% of men.

Men as a whole seem to have more faith in the longevity of the crypto market, with 35% of male respondents adopting a hold “forever” approach and noting that they will keep their cryptocurrency for longer than five years. This squares with the finding that men are more interested than women in investing in cryptocurrency to diversify their portfolios.

Source: Cardify

Take-Away

As trends continuously change over time, investors are best served by staying aware of the landscape and evaluating how demand for different opportunities may also evolve. A flow of “new” money into the markets, and presumably out of bank accounts or discretionary income, will impact where the money is coming from and where it is moving to.

Channelchek is always keeping an eye on trends and reporting to our readers. Be sure to register and stay aware of what we see that may impact your investment outcomes.

Suggested Reading:


The Value of “FinTock” “Finfluencers”	The Benefits of DeFi


Does the Russell reconstitution Impact Small Cap Performance?	Casual Dining and Fast Serve Restaurants Benefit from Back to Work

Sources:

https://www.cardify.ai/reports/international-womens-day

https://www.inc.com/amy-nelson/women-drive-majority-of-consumer-purchasing-its-time-to-meet-their-needs.html

Stay up to date. Follow us:

Lineage Cell Therapeutics Set to Join Russell 3000® Index and Russell Microcap® Index

Posted on June 9, 2021 by Admin

Lineage Cell Therapeutics Set to Join Russell 3000® Index and Russell Microcap® Index

CARLSBAD, Calif.–(BUSINESS WIRE)–Jun. 9, 2021–

Lineage Cell Therapeutics, Inc.
(NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today that it is set to join the broad-market Russell 3000^® Index as well as the Russell Microcap^®Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the U.S. market opens on
June 28, 2021, according to a preliminary list of additions posted on
June 4, 2021, by FTSE Russell, a leading global index provider.

Annual Russell indexes reconstitution captures the 4,000 largest
U.S. stocks as of
May 7, 2021, ranking them by total market capitalization. Membership in the
U.S. all-cap Russell 3000^® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000^® Index or small-cap Russell 2000^® Index as well as the appropriate growth and value style indexes. Membership in the Russell Microcap^® Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.

“Lineage’s inclusion on the preliminary list of additions to the Russell 3000^® Index and the Russell Microcap^®Index reflects progress we have made to establish ourselves as a leader in cell therapy and regenerative medicine,” stated Brian M. Culley, Lineage’s CEO. “During the past year, we have delivered significant clinical, manufacturing, and business milestones which have created considerable value for our shareholders, and we intend to be diligent in our efforts to benefit from the explosive growth we believe the field of cell therapy will experience in the months and years ahead. We believe our inclusion in the Russell indexes will help broaden awareness of Lineage’s corporate mission and objectives among a wider audience of investors and help drive an increase in the liquidity of our stock.”

Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately
$10.6 trillion in assets are benchmarked against Russell’s US indexes. Russell indexes are part of FTSE Russell.

About FTSE Russell

FTSE Russell is a global index leader that provides innovative benchmarking, analytics and data solutions for investors worldwide. FTSE Russell calculates thousands of indexes that measure and benchmark markets and asset classes in more than 70 countries, covering 98% of the investable market globally. FTSE Russell index expertise and products are used extensively by institutional and retail investors globally. Approximately
$17.9 trillion is currently benchmarked to FTSE Russell indexes. For over 30 years, leading asset owners, asset managers, ETF providers and investment banks have chosen FTSE Russell indexes to benchmark their investment performance and create ETFs, structured products and index-based derivatives. A core set of universal principles guides FTSE Russell index design and management: a transparent rules-based methodology is informed by independent committees of leading market participants. FTSE Russell is focused on applying the highest industry standards in index design and governance and embraces the IOSCO Principles. FTSE Russell is also focused on index innovation and customer partnerships as it seeks to enhance the breadth, depth and reach of its offering. FTSE Russell is wholly owned by London Stock Exchange Group. For more information, visit www.ftserussell.com.

About Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage’s clinical programs are in markets with billion dollar opportunities and include three allogeneic (“off-the-shelf”) product candidates: (i) OpRegen^®, a retinal pigment epithelium transplant therapy in Phase 1/2a development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of acute spinal cord injuries; and (iii) VAC2, an allogeneic dendritic cell therapy produced from Lineage’s VAC technology platform for immuno-oncology and infectious disease, currently in Phase 1 clinical development for the treatment of non-small cell lung cancer. For more information, please visit www.lineagecell.com or follow the Company on Twitter @LineageCell.

Forward-Looking Statements

Lineage cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements. Forward-looking statements, in some cases, can be identified by terms such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “design,” “intend,” “expect,” “could,” “can,” “plan,” “potential,” “predict,” “seek,” “should,” “would,” “contemplate,” project,” “target,” “tend to,” or the negative version of these words and similar expressions. Such statements include, but are not limited to, statements relating to Lineage’s inclusion in the Russell indexes, anticipated growth in the field of cell therapy, and the potential benefits to Lineage and its shareholders as a result. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Lineage’s actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including risks and uncertainties inherent in Lineage’s business and other risks in Lineage’s filings with the
Securities and Exchange Commission (SEC). Lineage’s forward-looking statements are based upon its current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. Further information regarding these and other risks is included under the heading “Risk Factors” in Lineage’s periodic reports with the
SEC, including Lineage’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the
SEC and its other reports, which are available from the SEC’s website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Lineage undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

The information in this announcement about the Russell indexes and FTSE Russell was obtained from FTSE Russell. Lineage has not independently verified such information and there can be no assurance as to its accuracy.

Lineage Cell Therapeutics, Inc. IR
Ioana C. Hone
(ir@lineagecell.com)
(442) 287-8963

Solebury Trout IR
Gitanjali Jain Ogawa
(Gogawa@soleburytrout.com)
(646) 378-2949

Russo Partners – Media Relations
Nic Johnson or David Schull
Nic.johnson@russopartnersllc.com
David.schull@russopartnersllc.com
(212) 845-4242

Source:
Lineage Cell Therapeutics, Inc.

PDS Biotechnology Corp (PDSB) – Phase 2 Interim Analysis in HPV Shows Strong Response Rate

Posted on June 9, 2021 by Admin

Wednesday, June 09, 2021

PDS Biotechnology Corp (PDSB)
Phase 2 Interim Analysis in HPV Shows Strong Response Rate

PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is primarily engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.

Robert LeBoyer, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

PDS Biotech presented the first analysis from the Phase 2 trial testing PDS0101 in HPV16+ (human papilloma virus 16 positive) cancers. The data presentation was from the first 25 patients out of the target enrollment of 56 patients. The trial enrolls patients who have failed first-line treatments but were naïve to checkpoint inhibitors as well as those who had become refractory to checkpoint inhibitor treatment.

PDS0101 is a triple combination therapy containing Versimue, the bifunctional checkpoint inhibitor bintrafusp, and Il-12 as an immune cytokine. This combination is intended to allow the immune system to recognize the tumor cell, then activate both CD4+ helper and CD8+ killer T-cells for a potent and durable immune response. Survival for patients who tested HPV16+ was 89% compared with 57% for …

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.

Orion Group Holdings (ORN) – No Appeal on Rezoning Approval and Tampa Yard Sale Closed

Posted on June 9, 2021 by Admin

Wednesday, June 09, 2021

Orion Group Holdings (ORN)
No Appeal on Rezoning Approval and Tampa Yard Sale Closed

Orion Group Holdings, based in Houston, Texas, is a specialty construction company within the Marine and Industrial Construction sectors, with operations focused in the continental United States and Caribbean. Revenue is split roughly 50/50 between a Marine Construction segment that provides marine facility, pipeline and structural construction services and a Commercial Concrete segment that provides turnkey concrete services in the light commercial and structural construction markets.

Poe Fratt, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Tampa yard sale closing is a positive step forward. There was no appeal of the May 6th second reading and approval by a 4-1-2 vote of REZ-20-92 to rezone the West Tyson property to PD (planned development, etc) so the sale of the Tampa yard closed. The sale generated net proceeds of $22 million and a unquantified gain will be recognized.

Financial flexibility increases. Pro forma cash should approach $30 million in 2Q2021 and other asset sales of ~$5 million should close in 3Q2021. While the ERP program is under way, there is a strong preference for growth-oriented investments, like the renovation of an existing barge. Absent an acquisition, a dividend and/or a stock buyback seem possible since the one-year credit facility recently …

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

Euroseas Ltd. (ESEA) – Likely Positive Upcoming Fixtures Boost Price Target

Posted on June 9, 2021 by Admin

Wednesday, June 09, 2021

Euroseas Ltd. (ESEA)
Likely Positive Upcoming Fixtures Boost Price Target

Euroseas Ltd. provides ocean-going transportation services worldwide. The company owns and operates containerships that transport dry and refrigerated containerized cargoes, including manufactured products and perishables; and drybulk carriers that transport iron ore, coal, grains, bauxite, phosphate, and fertilizers. As of March 31, 2017, it had a fleet of seven containerships; and six drybulk carriers, including three Panamax drybulk carriers, one Handymax drybulk carrier, one Kamsarmax drybulk carrier, and one Ultramax drybulk carrier. The company was founded in 2005 and is based in Maroussi, Greece.

Poe Fratt, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Higher container rates positive for upcoming charters. Charters on four feeders and one intermediate expire before yearend 2021 and the renewal prospects remain strong. We estimate that the feeders (Spetses/Diamantis/Corfu/Evridiki) will secure longer term work at charter rates in the $20.0k-$25.0k/day range. At the same time, charter rates for the Oakland, an intermediate, appear to have moved up into the more than $40.0k/day range.

Increasing 2021 EBITDA estimate to $44.1 million based on TCE rates of $17.4k/day, up from $40.6 million based on TCE rates of $16.7k/day. Forward cover and about 89% of 2021 available days of 5,000 are booked at average rates of $15.2k/day and Contracted EBITDA is ~$32.8 million. We are estimating that the open days are filled at an average TCE rate slightly above $20.0k/day …

This research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

C-Suite Interview with Cocrystal Pharma (COCP) Interim Co-CEOs Sam Lee, President & James Martin, CFO

Posted on June 9, 2021 by Admin

Noble Capital Markets Senior Research Analyst Robert LeBoyer sits down with Cocrystal Pharma Interim Co-CEO & President Sam Lee and Interim Co-CEO & CFO James Martin for this exclusive interview.

Research, News, and Advanced Market Data on COCP

View all C-Suite Interviews

About Cocrystal Pharma

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics as treatments for serious and/or chronic viral diseases. We employ unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs. These technologies are designed to efficiently deliver small molecule therapeutics that are safe, effective, and convenient to administer. We have identified promising preclinical antiviral therapeutics that target the replication process of influenza virus, SARS-CoV-2 virus, and norovirus and have completed a Phase 2a trial targeting the hepatitis C virus.

Release – Stem Cell and Regenerative Medicine Action Award Honorees to be Recognized During Virtual World Stem Cell Summit, June 18 2021

Posted on June 9, 2021 by Admin

Stem Cell and Regenerative Medicine Action Award Honorees to be Recognized During Virtual World Stem Cell Summit, June 18, 2021

2021 Honorees include NFL Alumni Health, the Klein Family (Bob, Danielle and Rob), Feng Zhang, PhD and the Global Immunization Action Network Team (GIANT) and Joseph P. Vacanti, MD.

On June 18, 2021 at 7:00 PM EDT, Regenerative Medicine Foundation (RMF) will broadcast the Stem Cell and Regenerative Medicine Action Awards as part of the virtual 16th annual World Stem Cell Summit (WSCS) and Wake Forest Institute for Regenerative Medicine and RMF’s Regenerative Medicine Essentials Course, June 14-18.

Bernard Siegel, Executive Director of RMF said, “Through the Action Awards, outstanding individuals and organizations are recognized for their devotion to improving health and developing cures through advocacy, innovation, leadership, education and inspiration. This year’s honorees are truly an inspiration who have made remarkable contributions to the field. Notable achievements made even more impressive, under the cloud of the global pandemic.”

Meet the 2021 honorees:

Advocacy Award: NFL Alumni Health
Founded in 1967 by a small group of successful retired NFL players, NFL Alumni Association (NFL Alumni) is one of the oldest and well-respected retired player organizations in professional sports. More than 15,000 former NFL players are connected with NFL Alumni. In 2020, NFL Alumni launched NFL Alumni Health to expand its efforts to improve the health and wellness of NFL Alumni members, as well as the general community, through informational resources, programs, and services, in line with its mission which includes “Caring for Kids,” “Caring for our Own,” and “Caring for the Community.” NFL Alumni Health activities include its collaboration with CDC to raise awareness of the benefits of getting vaccinated against COVID-19. NFL Alumni Health has also launched a program to educate its membership—and the public—about the potential benefits of regenerative medicine and cell-based therapies, and the questions patients should be asking as they seek out safe, effective and approved treatments. The very future of contact sports in America might depend upon the long-term treatment of our heroes of the gridiron and NFL Alumni Health leads the way.

Leadership & Advocacy Award: Bob Klein, Danielle Klein, Rob Klein
A new multi-billion dollar California ballot initiative to fund stem cell research for better treatments and cures for chronic diseases and illnesses was on the ballot in 2020. All the pundits said it couldn’t be done; it just wasn’t the time. Against all odds, and during a world altering pandemic, Proposition 14 not only qualified for the November ballot; but, it was passed, authorizing $5.5 billion in new funding for the continued operation of the California Institute for Regenerative Medicine (CIRM). The California agency’s research funding had already led to over 90 clinical trials, and 3,000 peer reviewed published discoveries. However, its funding had been exhausted, leaving highly promising research without the support needed to make it through vital stages of basic research, therapy development, and clinical trials, so that this research will fulfill its principal purpose of benefiting the patients that so desperately need the therapies that will result.

The entire Klein family provided essential leadership. Bob, Danielle and Rob Klein are a family of patient advocates who have made it their mission to ensure funding for stem cell and genetic therapy research remains a priority. Bob and Danielle served as Co-Chairs, and Rob served as the President of the campaign. Prop 14 would have never passed without their tenacity and devotion to the cause. They credit the initiative’s passage, in large part, to endorsement from over 100 patient advocacy groups, and a dedicated campaign team fighting for better treatments and cures for their families and loved ones.

Pathfinder Award: Feng Zhang, PhD
Feng Zhang is a molecular biologist who has developed novel molecular technologies for studying the brain. He pioneered the development of CRISPR-cas9 as a genome editing tool and has substantially expanded the use of new CRISPR tools, including RNA-targeting CRISPR-Cas13 systems and CRISPR-associated transposon systems, which can be used for gene insertion. One day, CRISPR might be harnessed to treat and possibly cure debilitating medical conditions such as Sickle Cell Anemia, Duchenne Muscular Dystrophy, Huntington’s Disease, HIV and cancers. Zhang is currently a core institute member of the Broad Institute of MIT and Harvard, as well as an investigator at the McGovern Institute for Brain Research at MIT, the James and Patricia Poitras Professor of Neuroscience at MIT, and a professor at MIT, with joint appointments in the departments of Brain and Cognitive Sciences and Biological Engineering. Zhang is also an investigator at the Howard Hughes Medical Institute.

Education Award: Global Immunization Action Network Team (GIANT)
The Global Immunization Action Network Team (GIANT) works to improve global public health outcomes by combating vaccine hesitancy through effective, sensitive, science-based communication and education. Throughout the COVID-19 pandemic, their extraordinary team has provided important, credible and factual information for people and communities to embrace immunization with trust and confidence. Without health literacy, public health will fail. GIANT presents a novel and timely topic to the World Stem Cell Summit agenda, Health Literacy: Stem Cell Science, Vaccine Development & Confidence in the Age of the Covid Pandemic and Infodemic.

Lifetime Achievement Award: Joseph P. Vacanti, MD
Dr. Joseph Vacanti is Surgeon-in-Chief and Chief of Pediatric Surgery at Mass General Hospital for Children. He is also Director of the Pediatric Transplant Program and co-director of the MGH Center for Regenerative Medicine. He has been active in clinical innovation and research in the field of regenerative medicine for more than three decades. Dr. Vacanti continues to study the creation of artificial organs using a biodegradable polymer scaffold to develop and shape tissue. Dr. Vacanti was a founding co-president of the Tissue Engineering Regenerative Medicine International Society (TERMIS). RMF recognizes his lifetime of dedication and genius.

Media Contact:
Joseph Dawson
Communications Director
Regenerative Medicine Foundation
joseph@regmedfoundation

Release – Helius Medical Technologies to Participate in Noble Capital Markets Virtual Road Show Series

Posted on June 9, 2021 by Admin

Helius Medical Technologies, Inc. to Participate in Noble Capital Markets’ Virtual Road Show Series

NEWTOWN, Pa., June 08, 2021 (GLOBE NEWSWIRE) — Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM:CA), (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced its participation in Noble Capital Markets’ Virtual Road Show Series, presented by Channelchek, which is scheduled for Thursday, June 10, 2021.

The event will feature a corporate presentation followed by a Q&A session proctored by Noble Capital Markets’ Senior Research Analyst, Joe Gomes, featuring questions submitted by the audience.

The live webcast of the event is scheduled for June 10, 2021, at 1:00 p.m. Eastern. Register for the webcast here. A recording will be available on Channelchek and under the ‘Events’ section of the Helius Medical Technologies investor relations website at https://heliusmedical.com/index.php/investor-relations/events/upcoming-events.

About
Helius Medical Technologies, Inc.

Helius Medical Technologies is a neurotech company focused on neurological wellness. The Company’s purpose is to develop, license and acquire unique and non-invasive platform technologies that amplify the brain’s ability to heal itself. The Company’s first commercial product is the Portable Neuromodulation Stimulator (PoNS
^TM). For more information, visit www.heliusmedical.com.

About the PoNS^TM Device and PoNS Treatment^TM

The Portable Neuromodulation Stimulator (PoNS^TM) is an innovative non-surgical device, inclusive of a controller and mouthpiece, which delivers electrical stimulation to the surface of the tongue to provide treatment of gait deficit. The PoNS device is indicated for use in the United States as a short term treatment of gait deficit due to mild-to-moderate symptoms from multiple sclerosis (“MS”) and is to be used as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and over by prescription only. It is authorized for sale in Canada as a class II, non-implantable, medical device intended as a short term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from MS, and chronic balance deficit due to mild-to-moderate traumatic brain injury (“mmTBI”) and is to be used in conjunction with physical therapy. The PoNS^TM is an investigational medical device in the European Union (“EU”) and Australia (“AUS”). It is currently under premarket review by the AUS Therapeutic Goods Administration.

Investor Relations Contact:

Westwicke Partners on behalf of Helius Medical Technologies, Inc.
Jack Powell, Vice President
investorrelations@heliusmedical.com

Release – Comtech Telecommunications Corp. Announces Results for Its Fiscal 2021 Third Quarter and Updates Its Financial Targets for Fiscal 2021

Posted on June 9, 2021 by Admin

Comtech Telecommunications Corp. Announces Results for Its Fiscal 2021 Third Quarter and Updates Its Financial Targets for Fiscal 2021

MELVILLE, N.Y.–(BUSINESS WIRE)–Jun. 8, 2021–
June 8, 2021—
Comtech Telecommunications Corp. (NASDAQ: CMTL) today reported its operating results for the third fiscal quarter ended
April 30, 2021 and updated its financial targets for fiscal 2021.

Fiscal 2021 Third Quarter Highlights

Consolidated net sales of
$139.4 million and Adjusted EBITDA of
$17.7 million (or 12.7% of consolidated net sales). Adjusted EBITDA, which significantly exceeded
Comtech’s expectation for its third quarter of fiscal 2021, is a non-GAAP financial measure that is reconciled to the most directly comparable GAAP financial measure and is more fully defined below.

With bookings of
$115.9 million, the Company achieved a book-to-bill ratio (a measure defined as bookings divided by net sales) of 0.83 during its third quarter of fiscal 2021. Backlog as of
April 30, 2021 was
$636.5 million. The total value of multi-year contracts that
Comtech has received is substantially higher than its reported backlog. When adding Comtech’s backlog and the total unfunded value of multi-year contracts that
Comtech has received and for which it expects future orders, its revenue visibility approximates
$1.1 billion.

The Company incurred an aggregate of
$5.3 million of acquisition plan expenses due to the
April 2021 settlement of litigation related to the 2019 acquisition of GD NG-911 as well as the
March 2021 closing of the UHP acquisition. The integration of UHP into Comtech’s satellite ground station product line is well underway, and it does not expect to incur any significant acquisition plan expenses for the remainder of fiscal 2021.

The Company’s annual effective income tax rate was 11.5%, excluding a net discrete tax expense of
$0.2 million.

Comtech reported GAAP operating income of
$2.4 million, GAAP net income of
$0.8 million and GAAP net income per diluted share (“EPS”) of
$0.03 for the third quarter of fiscal 2021. Non-GAAP operating income was
$8.9 million, Non-GAAP net income was
$6.8 million and Non-GAAP EPS was
$0.26. These Non-GAAP amounts exclude acquisition plan expenses, restructuring costs, COVID-19 related costs, strategic emerging technology costs for next-generation satellite technology and a net discrete tax expense. Non-GAAP amounts are reconciled to the most directly comparable GAAP financial measures in the table below.

Comtech generated GAAP operating cash flows of
$6.8 million during the third quarter and had
$39.2 million of cash and cash equivalents and total debt outstanding of
$215.0 million as of
April 30, 2021.

Commenting on the Company’s third quarter fiscal 2021 performance, Fred Kornberg, Chairman of the Board and Chief Executive Officer, stated, “Thanks to the hard work of all of our team members, we achieved solid operating performance and have recently secured important contract awards that bode well for our future. We are continuing to invest in new state-of-the-art production and engineering facilities as well as new next-generation wireless technology solutions that we believe our customers will want in the post-COVID-19 pandemic economic recovery. Looking forward, we are confident that we will have a strong finish to fiscal 2021 and achieve growth in fiscal 2022.”

COMMENTS AND FINANCIAL TARGETS FOR EXPECTED FISCAL 2021 PERFORMANCE

Comtech is making the following comments on expected fiscal 2021 performance:

Comtech expects fiscal 2021 consolidated net sales to be in a range of
$580.0 million to
$590.0 million. This updated target primarily reflects a change in anticipated revenues in its Government Solutions segment due to the
U.S. government’s
April 2021 announcement to fully withdraw troops from
Afghanistan as well as other program changes. At the same time, the Company’s effort to streamline business operations are paying off and it continues to target Adjusted EBITDA in a range of
$74.0 million to
$76.0 million for fiscal 2021.

During the third quarter,
Comtech incurred
$0.3 million of strategic emerging technology costs for next-generation satellite technology to advance its solutions offerings to be used with new broadband satellite constellations. The Company is evaluating this new market in relation to its long-term business strategies, and it may incur additional costs over the next twelve months.

As disclosed in the Company’s Quarterly Report on Form 10-Q filed with the
Securities and Exchange Commission (“SEC”) today, at the start of Comtech’s fourth quarter of fiscal 2021, it entered into a multi-year agreement enabling a customer to potentially order hundreds of millions of dollars of its next-generation satellite earth station technology. Shortly after
Comtech signed this agreement, it received its first order valued at more than
$13.0 million to make certain customizations on behalf of this customer. Work on these efforts has commenced immediately.

Comtech expects fiscal 2021 revenue in its Commercial Solutions segment to be slightly higher than the amount it achieved in fiscal 2020, primarily due to: (i) strong demand for
Comtech’s public safety technology solutions; (ii) delivering 5G virtual mobile location-based technology solutions for two
U.S. tier-one mobile network operators; (iii) contract performance in support of a critical
U.S. Air Force and
U.S. Army Anti-jam Modem (“A3M”) program under the
U.S. Space Force’s Space and Missile Systems Center (“SMC”) agency; and (iv) deliveries of SLM-5650B satellite modems and firmware related to a previously awarded contract from the
U.S. Naval Information Warfare Systems Command.

Comtech expects fiscal 2021 revenue in its Government Solutions segment to be significantly lower than the amount it achieved in fiscal 2020. Fiscal 2021 is anticipated to reflect significantly lower sales of field support services, partially offset by demand for: (i) Manpack Satellite Terminals, networking equipment and other advanced VSAT products by the
U.S. Army; (ii) ongoing sustainment services for the
U.S. Army for the AN/TSC-198A SNAP terminal; (iii) sustainment services for the
U.S. Army’s Project Manager Mission Command (“PM MC”) Blue Force Tracking (“BFT-1”) program; and (iv) Joint Cyber Analysis Course (“JCAC”) training solutions.

During its third quarter of fiscal 2021,
Comtech initiated an effort to improve efficiencies and streamline operations in its Government Solutions segment. These efforts, which remain ongoing, include the consolidation of certain administrative and operating functions in both its
Florida and
Maryland locations. In addition,
Comtech has started to shift production of many of its key satellite earth station products from its existing
Tempe, Arizona locations to a new 146,000 square foot facility in
Chandler, Arizona as well as the combination of certain related functions. This new facility is located less than 10 miles from its current facilities and is expected to support anticipated growth and long-term business goals. Over time, these efforts are expected to improve consolidated Adjusted EBITDA margins.

Additional information about the Company’s third quarter fiscal 2021 performance and updated fiscal 2021 targets can be found in the Company’s Form 10-Q as filed with the
SEC. Because of the pandemic’s continuing impact on global business conditions, the Company is not providing any GAAP operating income, GAAP net income or GAAP EPS guidance or a reconciliation of the Company’s projected Adjusted EBITDA results to the most comparable GAAP measure, as such a reconciliation cannot be prepared without unreasonable effort. For the same reasons, the Company is unable to address the probable significance of the unavailable information, which could be material to future results.

Conference Call

The Company has scheduled an investor conference call for
4:30 PM (ET) on
Tuesday, June 8, 2021. Investors and the public are invited to access a live webcast of the conference call from the Investor Relations section of the
Comtech website at www.comtechtel.com. Alternatively, investors can access the conference call by dialing (800) 895-3361 (domestic), or (785) 424-1062 (international) and using the conference I.D. ”
Comtech.” A replay of the conference call will be available for seven days by dialing (800) 839-4568 or (402) 220-2681. In addition, an updated investor presentation is available on the Company’s website.

About Comtech

Comtech Telecommunications Corp. is a leader in the global communications market headquartered in
Melville, New York. With a passion for customer success,
Comtech designs, produces and markets advanced secure wireless solutions to more than 1,000 customers in more than 100 countries. For more information, please visit www.comtechtel.com.

Cautionary Statement Regarding Forward-Looking Statements

Certain information in this press release contains forward-looking statements, including but not limited to, information relating to the Company’s future performance and financial condition, plans and objectives of the Company’s management and the Company’s assumptions regarding such future performance, financial condition, and plans and objectives that involve certain significant known and unknown risks and uncertainties and other factors not under the Company’s control which may cause its actual results, future performance and financial condition, and achievement of plans and objectives of the Company’s management to be materially different from the results, performance or other expectations implied by these forward-looking statements. These factors include, among other things: the possibility that the expected synergies and benefits from recent acquisitions will not be fully realized, or will not be realized within the anticipated time periods; the risk that the acquired businesses will not be integrated with the Company successfully; the possibility of disruption from recent acquisitions, making it more difficult to maintain business and operational relationships or retain key personnel; the risk that the Company will be unsuccessful in implementing a tactical shift in its Government Solutions segment away from bidding on large commodity service contracts and toward pursuing contracts for its niche products with higher margins; the nature and timing of receipt of, and the Company’s performance on, new or existing orders that can cause significant fluctuations in net sales and operating results; the timing and funding of government contracts; adjustments to gross profits on long-term contracts; risks associated with international sales; rapid technological change; evolving industry standards; new product announcements and enhancements, including the risks associated with expanding the sales of the
Company’s Heights^TM Network Platform (“HEIGHTS”); changing customer demands and or procurement strategies; changes in prevailing economic and political conditions; changes in the price of oil in global markets; changes in foreign currency exchange rates; risks associated with the Company’s legal proceedings, customer claims for indemnification, and other similar matters; risks associated with the Company’s obligations under its Credit Facility; risks associated with the Company’s large contracts; risks associated with the COVID-19 pandemic; and other factors described in this and the Company’s other filings with the
Securities and Exchange Commission.

COMTECH TELECOMMUNICATIONS CORP. AND SUBSIDIARIES Condensed Consolidated Statements of Operations (Unaudited)

	Three months ended April 30,						Nine months ended April 30,
	2021			2020			2021			2020
Net sales	$	139,376,000		$	135,121,000		$	435,886,000		$	467,042,000
Cost of sales	86,360,000			82,120,000			276,982,000			289,872,000
Gross profit	53,016,000			53,001,000			158,904,000			177,170,000

Expenses:
Selling, general and administrative	26,997,000			32,313,000			83,999,000			93,538,000
Research and development	13,092,000			12,324,000			37,391,000			40,925,000
Amortization of intangibles	5,310,000			5,517,000			15,671,000			15,952,000
Acquisition plan expenses	5,267,000			5,983,000			99,807,000			14,397,000
	50,666,000			56,137,000			236,868,000			164,812,000

Operating income (loss)	2,350,000			(3,136,000		)	(77,964,000		)	12,358,000

Other expenses (income):
Interest expense	1,518,000			1,504,000			5,233,000			4,924,000
Interest (income) and other	(276,000		)	108,000			(276,000		)	37,000

Income (loss) before provision for (benefit from) income taxes	1,108,000			(4,748,000		)	(82,921,000		)	7,397,000
Provision for (benefit from) income taxes	316,000			(759,000		)	(2,078,000		)	1,503,000

Net income (loss)	$	792,000		$	(3,989,000	)	$	(80,843,000	)	$	5,894,000
Net income (loss) per share:
Basic	$	0.03		$	(0.16	)	$	(3.12	)	$	0.24
Diluted	$	0.03		$	(0.16	)	$	(3.12	)	$	0.24

Weighted average number of common shares outstanding – basic	25,911,000			24,982,000			25,875,000			24,730,000

Weighted average number of common and common equivalent shares outstanding – diluted	26,266,000			24,982,000			25,875,000			24,892,000

COMTECH TELECOMMUNICATIONS CORP. AND SUBSIDIARIES Condensed Consolidated Balance Sheets

	April 30, 2021			July 31, 2020
	(Unaudited)			(Audited)
Assets
Current assets:
Cash and cash equivalents	$	39,198,000		$	47,878,000
Accounts receivable, net	144,132,000			126,816,000
Inventories, net	83,106,000			82,302,000
Prepaid expenses and other current assets	25,801,000			20,101,000
Total current assets	292,237,000			277,097,000
Property, plant and equipment, net	29,366,000			27,037,000
Operating lease right-of-use assets, net	47,296,000			30,033,000
Goodwill	347,780,000			330,519,000
Intangibles with finite lives, net	274,048,000			258,019,000
Deferred financing costs, net	1,839,000			2,391,000
Other assets, net	6,026,000			4,551,000
Total assets	$	998,592,000		$	929,647,000
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$	33,277,000		$	23,423,000
Accrued expenses and other current liabilities	97,602,000			85,161,000
Operating lease liabilities, current	8,755,000			8,247,000
Dividends payable	2,600,000			2,468,000
Contract liabilities	56,192,000			40,250,000
Interest payable	227,000			163,000
Total current liabilities	198,653,000			159,712,000
Non-current portion of long-term debt, net	215,000,000			149,500,000
Operating lease liabilities, non-current	41,542,000			24,109,000
Income taxes payable	2,588,000			1,963,000
Deferred tax liability, net	24,495,000			17,637,000
Long-term contract liabilities	8,997,000			9,596,000
Other liabilities	15,695,000			17,831,000
Total liabilities	506,970,000			380,348,000
Commitments and contingencies
Stockholders’ equity:
Preferred stock, par value $.10 per share; shares authorized and unissued 2,000,000	—			—
Common stock, par value $0.10 per share; authorized 100,000,000 shares; issued 41,102,215 shares and 39,924,439 shares at April 30, 2021 and July 31, 2020, respectively	4,110,000			3,992,000
Additional paid-in capital	601,029,000			569,891,000
Retained earnings	328,332,000			417,265,000
	933,471,000			991,148,000
Less:
Treasury stock, at cost (15,033,317 shares at April 30, 2021 and July 31, 2020)	(441,849,000		)	(441,849,000		)
Total stockholders’ equity	491,622,000			549,299,000
Total liabilities and stockholders’ equity	$	998,592,000		$	929,647,000

COMTECH TELECOMMUNICATIONS CORP.
AND SUBSIDIARIES
Reconciliation of Non-GAAP Financial Measures to GAAP Financial Measures
(Unaudited)

Use of Non-GAAP Financial Measures

In order to provide investors with additional information regarding its financial results, this press release contains “Non-GAAP financial measures” under the rules of the
SEC. The Company’s Adjusted EBITDA is a Non-GAAP measure that represents earnings (loss) before income taxes, interest (income) and other, write-off of deferred financing costs, interest expense, amortization of stock-based compensation, amortization of intangible assets, depreciation expense, estimated contract settlement costs, settlement of intellectual property litigation, acquisition plan expenses, restructuring costs, COVID-19 related costs, strategic emerging technology costs (for next-generation satellite technology), facility exit costs, strategic alternatives analysis expenses and other. The Company’s definition of Adjusted EBITDA may differ from the definition of EBITDA or Adjusted EBITDA used by other companies and therefore may not be comparable to similarly titled measures used by other companies. Adjusted EBITDA is also a measure frequently requested by the Company’s investors and analysts. The Company believes that investors and analysts may use Adjusted EBITDA, along with other information contained in its
SEC filings, in assessing the Company’s performance and comparability of its results with other companies. The Company’s Non-GAAP measures for consolidated operating income, net income and net income per diluted share reflect the GAAP measures as reported, adjusted for certain items as discussed below. These Non-GAAP financial measures have limitations as an analytical tool as they exclude the financial impact of transactions necessary to conduct the Company’s business, such as the granting of equity compensation awards, and are not intended to be an alternative to financial measures prepared in accordance with GAAP. These measures are adjusted as described in the reconciliation of GAAP to Non-GAAP in the below tables, but these adjustments should not be construed as an inference that all of these adjustments or costs are unusual, infrequent or non-recurring. Non-GAAP financial measures should be considered in addition to, and not as a substitute for or superior to, financial measures determined in accordance with GAAP. Investors are advised to carefully review the GAAP financial results that are disclosed in the Company’s
SEC filings. The Company has not quantitatively reconciled its fiscal 2021 Adjusted EBITDA target to the most directly comparable GAAP measure because items such as stock-based compensation, adjustments to the provision for income taxes, amortization of intangibles and interest expense, which are specific items that impact these measures, have not yet occurred, are out of the Company’s control, or cannot be predicted. For example, quantification of stock-based compensation expense requires inputs such as the number of shares granted and market price that are not currently ascertainable. Accordingly, reconciliations to the Non-GAAP forward looking metrics are not available without unreasonable effort and such unavailable reconciling items could significantly impact the Company’s financial results.

	Three months ended						Nine months ended					Fiscal
	April 30,						April 30,					Year
	2021			2020			2021			2020		2020
Reconciliation of GAAP Net Income (Loss) to Adjusted EBITDA:
Net income (loss)	$	792,000		$	(3,989,000	)	$	(80,843,000	)	$	5,894,000	$	7,020,000
Provision for (benefit from) income taxes	316,000			(759,000		)	(2,078,000		)	1,503,000		2,290,000
Interest (income) and other	(276,000		)	108,000			(276,000		)	37,000		(190,000		)
Interest expense	1,518,000			1,504,000			5,233,000			4,924,000		6,054,000
Amortization of stock-based compensation	1,204,000			981,000			3,190,000			3,098,000		9,275,000
Amortization of intangibles	5,310,000			5,517,000			15,671,000			15,952,000		21,595,000
Depreciation	2,274,000			2,650,000			7,283,000			8,022,000		10,561,000
Estimated contract settlement costs	—			476,000			—			444,000		444,000
Acquisition plan expenses	5,267,000			5,983,000			99,807,000			14,397,000		20,754,000
Restructuring costs	594,000			—			1,195,000			—		—
COVID-19 related costs	416,000			—			576,000			—		—
Strategic emerging technology costs	315,000			—			315,000			—		—
Adjusted EBITDA	$	17,730,000		$	12,471,000		$	50,073,000		$	54,271,000	$	77,803,000

In addition, a reconciliation of
Comtech’s GAAP consolidated operating income (loss), net income (loss) and net income (loss) per diluted share to the corresponding non-GAAP measures is shown in the tables below for the three and nine months ended
April 30, 2021 and 2020:

	April 30, 2021
	Three months ended									Nine months ended
	Operating Income			Net Income			Net Income per Diluted Share*			Operating (Loss) Income			Net (Loss) Income			Net (Loss) Income per Diluted Share*
Reconciliation of GAAP to Non-GAAP Earnings:
GAAP measures, as reported	$	2,350,000		$	792,000		$	0.03		$	(77,964,000	)	$	(80,843,000	)	$	(3.12	)
Acquisition plan expenses	5,267,000			4,661,000			0.18			99,807,000			96,379,000			3.70
Restructuring costs	594,000			526,000			0.02			1,195,000			1,058,000			0.04
COVID-19 related costs	416,000			368,000			0.01			576,000			510,000			0.02
Strategic emerging technology costs	315,000			279,000			0.01			315,000			279,000			0.01
Interest expense	—			—			—			—			1,043,000			0.04
Net discrete tax expense (benefit)	—			189,000			0.01			—			(592,000		)	(0.02		)
Non-GAAP measures	$	8,942,000		$	6,815,000		$	0.26		$	23,929,000		$	17,834,000		$	0.69

	April 30, 2020
	Three months ended									Nine months ended
	Operating (Loss) Income			Net (Loss) Income			Net (Loss) Income per Diluted Share*			Operating Income			Net Income			Net Income per Diluted Share*
Reconciliation of GAAP to Non-GAAP Earnings:
GAAP measures, as reported	$	(3,136,000	)	$	(3,989,000	)	$	(0.16	)	$	12,358,000		$	5,894,000		$	0.24
Acquisition plan expenses	5,983,000			4,128,000			0.16			14,397,000			9,934,000			0.40
Estimated contract settlement costs	476,000			328,000			0.01			444,000			306,000			0.01
Net discrete tax expense (benefit)	—			713,000			0.03			—			(790,000		)	(0.03		)
Non-GAAP measures	$	3,323,000		$	1,180,000		$	0.05		$	27,199,000		$	15,344,000		$	0.62

	Fiscal Year 2020
	Operating Income			Net Income			Net Income per Diluted Share*
Reconciliation of GAAP to Non-GAAP Earnings:
GAAP measures, as reported	$	15,174,000		$	7,020,000		$	0.28
Estimated contract settlement costs	444,000			280,000			0.01
Acquisition plan expenses	20,754,000			13,075,000			0.53
Net discrete tax benefit	—			(1,155,000		)	(0.05		)
Non-GAAP measures	$	36,372,000		$	19,220,000		$	0.77

* Per share amounts may not foot due to rounding. Non-GAAP EPS adjustments for the nine months ended
April 30, 2021 were computed using 26,016,000 weighted average diluted shares outstanding during the respective period. In addition, non-GAAP EPS adjustments for three months ended
April 30, 2020 were computed using 25,058,000 weighted average diluted shares outstanding during the respective period.

Media Contact:
Michael D. Porcelain, President and Chief Operating Officer
(631) 962-7000
Info@comtechtel.com

Source:
Comtech Telecommunications Corp.

Release – Comtech Telecommunications Corp. Declares 0.10 Per Share Quarterly Cash Dividend

Posted on June 9, 2021 by Admin

Comtech Telecommunications Corp. Declares $0.10 Per Share Quarterly Cash Dividend

MELVILLE, N.Y.–(BUSINESS WIRE)–Jun. 8, 2021–
June 8, 2021—
Comtech Telecommunications Corp. (NASDAQ: CMTL) announced today that its Board of Directors declared a quarterly cash dividend of
$0.10 per share, payable on
August 20, 2021, to shareholders of record at the close of business on
July 21, 2021. The dividend is the Company’s forty-fourth consecutive quarterly dividend. Future dividends remain subject to compliance with financial covenants under the Company’s secured credit facility as well as Board approval.

Certain information in this press release contains statements that are forward-looking in nature and involve certain significant risks and uncertainties. Actual results could differ materially from such forward-looking information. The Company’s
Securities and Exchange Commission filings identify many such risks and uncertainties. Any forward-looking information in this press release is qualified in its entirety by the risks and uncertainties described in such
Securities and Exchange Commission filings.

Media Contacts:
Michael D. Porcelain, President and Chief Operating Officer
(631) 962-7000
Info@comtechtel.com

Source:
Comtech Telecommunications Corp.

Release – Lineage Cell Therapeutics Set to Join Russell 3000 Index and Russell Microcap Index

Posted on June 9, 2021 by Admin

Lineage Cell Therapeutics Set to Join Russell 3000® Index and Russell Microcap® Index

About FTSE Russell

About Lineage Cell Therapeutics, Inc.

Forward-Looking Statements

Source:
Lineage Cell Therapeutics, Inc.

Release – Esports Entertainment Group Partners with CEAC to Host Inaugural Cinema and Esports Event

Posted on June 9, 2021 by Admin

Esports Entertainment Group Partners with CEAC to Host Inaugural Cinema & Esports Event

Event will explore how cinemas can gain new revenue streams and the esports community can add venues for viewing and practices

Newark, New Jersey–(Newsfile Corp. – June 9, 2021) – Esports Entertainment Group, Inc. (NASDAQ: GMBL) (NASDAQ: GMBLW) (or the “Company”), an esports entertainment and online gambling company, today announced a partnership with Cinema Esports Alliance Co., an organization dedicated to the growth of esports in cinema, to host a virtual event to bridge the gap and open the door of communication between the cinema and esports industries. The inaugural event will delve deeper into how both industries can support each other. While cinemas are eager to find new revenue streams, the esports community seeks new venues for practices and viewing parties.

“We are excited to partner with the CEAC to help cinemas attract the gamer community into their facilities,” stated Grant Johnson, CEO of Esports Entertainment Group. “We believe we have a turnkey, fully-integrated esports solution that can support cinema exhibition of esports including tournaments and onsite infrastructure.”

“Cinemas have looked at esports with interest because the profile of the gamer is similar to that of the avid moviegoer,” added Heather Blair, founder of CEAC. “With concern for lack of or inconsistent movie content, cinemas are motivated to seek other types of entertainment to offer their customers and attract new ones. This event pairs experts in several fields willing to discuss their successes and pitfalls of their past and current projects and programs surrounding this topic.”

The event will take place virtually on June 22 at 10:00 a.m. PST/1:00 p.m. EST with registration open to all, but prior RSVP
required. The speakers will include Magnus Leppäniemi , President of Esports at EEG, Glen Elliott, founder of Esports Gaming League, Scott Russel, Head of Gaming APAC at Blackhawk Network, and Adam Saks, CEO of Level Up Entertainment/UltraStar Multi-tainment.

About Esports Entertainment Group

Esports Entertainment Group is a full stack esports and online gambling company fueled by the growth of video-gaming and the ascendance of esports with new generations. Our mission is to help connect the world at large with the future of sports entertainment in unique and enriching ways that bring fans and gamers together. Esports Entertainment Group and its affiliates are well-poised to help fans and players to stay connected and involved with their favorite esports. From traditional sports partnerships with professional NFL/NHL/NBA/FIFA teams, community-focused tournaments in a wide range of esports, and boots-on-the-ground LAN cafes, EEG has influence over the full-spectrum of esports and gaming at all levels. The Company maintains offices in New Jersey, the UK and Malta. For more information visit www.esportsentertainmentgroup.com.

FORWARD-LOOKING STATEMENTS

The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The safe harbor for forward-looking statements contained in the Securities Litigation Reform Act of 1995 protects companies from liability for their forward-looking statements if they comply with the requirements of the Act.

Contact:

U.S. Investor Relations
RedChip Companies, Inc.
Dave Gentry
407-491-4498

dave@redchip.com

Media & Investor Relations Inquiries
Jeff@esportsentertainmentgroup.com

Disclosure:

RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.

The information contained herein is not intended to be used as the basis for investment decisions and should not be construed as advice intended to meet the particular investment needs of any investor. The information contained herein is not a representation or warranty and is not an offer or solicitation of an offer to buy or sell any security. To the fullest extent of the law, RedChip Companies, Inc., our specialists, advisors, and partners will not be liable to any person or entity for the quality, accuracy, completeness, reliability or timeliness of the information provided, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information provided to any person or entity (including but not limited to lost profits, loss of opportunities, trading losses and damages that may result from any inaccuracy or incompleteness of this information).

Stock market investing is inherently risky. RedChip Companies is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles or in other investor relations materials or presentations that it publishes electronically or in print.

We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission (“SEC”) at www.sec.gov.

Esports Entertainment Group, Inc. (GMBL) is a client of RedChip Companies, Inc. GMBL agreed to pay RedChip Companies, Inc. a $4,000 monthly cash fee, beginning in June 2018, and 225,000 shares of Rule 144 stock for RedChip investor awareness services.

Investor awareness services and programs are designed to help small-cap companies communicate their investment characteristics. RedChip investor awareness services include the preparation of a research profile(s), multimedia marketing, and other awareness services.

Release – electroCore Completes Sale of 1.4 Million of NJ NOL Tax Benefits

Posted on June 9, 2021 by Admin

electroCore Completes Sale of $1.4 Million of NJ NOL Tax Benefits

ROCKAWAY, NJ,
June 09, 2021 (GLOBE NEWSWIRE) —
electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that it has completed the sale of
$1.4 million of its available tax benefits through the New Jersey Economic Development Authority’s Technology Business Tax Certificate Transfer program for fiscal years 2019 and 2020. As a result, the Company has received approximately
$1.4 million in non-dilutive cash from the sale of these net operating loss (NOL) tax benefits.

“This transaction strengthens our balance sheet and further improves our cash position,” commented Brian Posner, Chief Financial Officer of electroCore. “The funding will extend our efforts in commercializing gammaCore and fortify our ability to expand our non-invasive vagus nerve stimulation (nVNS) therapy into new markets.”

The New Jersey Technology Business Tax Certificate Transfer program enables qualified, NJ-based technology or biotechnology companies with NOLs and fewer than 225 U.S. employees to sell a percentage of their NOL tax credits to unrelated profitable corporations. NOLs may be sold for at least 80 percent of their value, up to a maximum lifetime benefit of
$15 million per business. This allows qualifying technology and biotechnology companies with NOLs to turn tax losses and credits into cash proceeds to fund their growth and operations, including research and development or other allowable expenditures.

About electroCore, Inc.

electroCore, Inc. is a commercial stage bioelectronic medicine company dedicated to improving patient outcomes through its platform non-invasive vagus nerve stimulation therapy initially focused on the treatment of multiple conditions in neurology. The company’s current indications are for the preventative treatment of cluster headache and migraine and acute treatment of migraine and episodic cluster headache.

For more information, visit www.electrocore.com.

About gammaCore^TM

gammaCore^TM (nVNS) is the first non-invasive, hand-held medical therapy applied at the neck as an adjunctive therapy to treat migraine and cluster headache through the utilization of a mild electrical stimulation to the vagus nerve that passes through the skin. Designed as a portable, easy-to-use technology, gammaCore can be self-administered by patients, as needed, without the potential side effects associated with commonly prescribed drugs. When placed on a patient’s neck over the vagus nerve, gammaCore stimulates the nerve’s afferent fibers, which may lead to a reduction of pain in patients.

gammaCore is FDA cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, and the acute and preventive treatment of migraine in adolescent (ages 12 and older) and adult patients. gammaCore is CE-marked in the European Union for the acute and/or prophylactic treatment of primary headache (Migraine, Cluster Headache, Trigeminal Autonomic Cephalalgias and Hemicrania Continua) and Medication Overuse Headache in adults.

gammaCore is contraindicated for patients if they:
- Have an active implantable medical device, such as pacemaker, hearing aid implant, or implanted electronic device
- Have a metallic device such as a stent, bone plate, or bone screw, implanted at or near the neck
- Are using another device at the same time (e.g., TENS Unit, muscle stimulator) or any portable electronic device (e.g., mobile phone)
Safety and efficacy of gammaCore have not been evaluated in the following patients:
- Patients diagnosed with narrowing of the arteries (carotid atherosclerosis)
- Patients who have had surgery to cut the vagus nerve in the neck (cervical vagotomy)
- Pediatric patients (less than 12 years of age)
- Pregnant women
- Patients with clinically significant hypertension, hypotension, bradycardia, or tachycardia

Please refer to the gammaCore Instructions for Use for all the important warnings and precautions before using or prescribing this product.

Forward-looking statement
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements regarding electroCore’s business prospects, its sales and marketing and product development plans, future cash flow projections, anticipated costs, its product portfolio or potential markets for its technologies, the availability and impact of payor coverage, the potential of nVNS generally and gammaCore in particular to treat COVID-19, and other statements that are not historical in nature, particularly those using terminology such as “anticipates,” “expects,” “believes,” “intends,” other words of similar meaning, derivations of such words and the use of future dates. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to obtain additional financing necessary to continue electroCore’s business, sales and marketing and product development plans, the uncertainties inherent in the development of new products or technologies, the ability to successfully commercialize gammaCore™, competition in the industry in which electroCore operates and general market conditions. All forward-looking statements are made as of the date of this press release, and electroCore undertakes no obligation to update forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should refer to all information set forth in this document and should also refer to the disclosure of risk factors set forth in the reports and other documents electroCore files with the
SEC, available at www.sec.gov.

Investors:
Rich CockrellCG Capital
404-736-3838
ecor@cg.capital

or

Media Contact:
Summer Diaz
electroCore
816-401-6333
summer.diaz@electrocore.com

Women’s Investing Involvement is Growing Dramatically

The Value of “FinTock” “Finfluencers”

The Benefits of DeFi

Does the Russell reconstitution Impact Small Cap Performance?

Casual Dining and Fast Serve Restaurants Benefit from Back to Work

Lineage Cell Therapeutics Set to Join Russell 3000® Index and Russell Microcap® Index

PDS Biotechnology Corp (PDSB)Phase 2 Interim Analysis in HPV Shows Strong Response Rate

Orion Group Holdings (ORN)No Appeal on Rezoning Approval and Tampa Yard Sale Closed

Euroseas Ltd. (ESEA)Likely Positive Upcoming Fixtures Boost Price Target

Research, News, and Advanced Market Data on COCP

View all C-Suite Interviews

Stem Cell and Regenerative Medicine Action Award Honorees to be Recognized During Virtual World Stem Cell Summit, June 18, 2021

Helius Medical Technologies, Inc. to Participate in Noble Capital Markets’ Virtual Road Show Series

Comtech Telecommunications Corp. Announces Results for Its Fiscal 2021 Third Quarter and Updates Its Financial Targets for Fiscal 2021

Comtech Telecommunications Corp. Declares $0.10 Per Share Quarterly Cash Dividend

Lineage Cell Therapeutics Set to Join Russell 3000® Index and Russell Microcap® Index

Esports Entertainment Group Partners with CEAC to Host Inaugural Cinema & Esports Event

electroCore Completes Sale of $1.4 Million of NJ NOL Tax Benefits

PDS Biotechnology Corp (PDSB)
Phase 2 Interim Analysis in HPV Shows Strong Response Rate

Orion Group Holdings (ORN)
No Appeal on Rezoning Approval and Tampa Yard Sale Closed

Euroseas Ltd. (ESEA)
Likely Positive Upcoming Fixtures Boost Price Target